We use cookies to help provide and enhance our service and tailor content and advertisements. Disable them / read more. By continuing or closing this message you agree to the use of cookies.
Lexis Nexis
Maximize merger arbitrage growth returns
Out maneuver the market and identify potential regulatory hurdles for mergers and acquisitions with MLex. Our exclusive market insight, analysis and commentary covers deals from pre-notification through notification, review and approval.
The world's leading hedge funds use the MLex DealRisk service to analyze deals through notification, review, approval and compliance with daily case updates on M&A clearance.
Gain perspective on global activist situations
Our Activist coverage seeks to put some of the world’s most significant activist situations into perspective, allowing investors to put breaking news on activist shareholdings into context and inform their decision-making.
Our journalists on the ground will join the dots on latest developments, providing background and insight on investor profiles and possible intent.
As reported first by MLex
Like to read the full text of these, or any other MLex insights? Request a trial subscription via the form at the bottom of the page.
Energizer set to win conditional EU approval for Spectrum Brands deal
7 December 2018
Alstom-Siemens deal to get recommendation of approval with remedies in Brazil
4 December 2018
IBM-Red Hat deal review disputed by DOJ, FTC
3 December 2018
Knauf, USG deal's impact on competition to be weakened by strong Chinese competitor
21 November 2018
Disney's Fox deal expected to secure EU approval
2 November 2018
Microsoft-GitHub deal cleared by DOJ
26 September 2018
Suzano-Fibria deal set for unconditional approval in Brazil
21 September 2018
Tronox, Cristal on track to win conditional EU approval
15 June 2018
KLA-Tencor, Orbotech file for South Korean merger clearance
14 June 2018
Linde-Praxair deal set for Brazilian clearance next week
7 June 2018
Northrop Grumman’s acquisition of Orbital ATK could receive US antitrust approval by mid-June
25 May 2018
Bayer-Monsanto deal hasn't received staff recommendation at US DOJ; decision expected by early April
2 March 18
Qualcomm still to refile NXP deal to China’s Mofcom as deadline looms
12 April 2018
Tronox, Cristal point to Chinese competition in EU hearing on titanium-dioxide deal
11 April 2018
Myer's board, management should remain, investor Wilson Asset Management says
19 September 2018
Suzano-Fibria deal set for unconditional approval in Brazil
21 September 2018
Review and learn from past merger decisions, EU Commission's chief economist urges
1 October 2018
Key Deals
Our coverage includes exclusive insight and analysis on the following key deals around the globe.
United States of America
AT&T/Time Warner
CVS/Aetna
Fresenius/NXStage
T-Mobile/Sprint
Tronox/Cristal
Thales/Gemalto
Amcor/Bemis
Illumina/Pacific Biosciences
IBM/Red Hat
Nexstar/Tribune
Bristol-Myers Squibb/Celgene
Fidelity National Financial/Stewart Information Services
The EU & UK
Innogy/EOn
Amcor/Bemis
Illumina/Pacific Biosciences
CommScope/ARRIS
IBM/Red Hat
Bristol-Myers Squibb/Celgene
Sainsbury's/Asda
Asia
KLA/Orbotech
Bristol-Myers Squibb/Celgene
Latin America
Disney/21st Century Fox
Amcor/Bemis
Meet our global experts
Below is a small selection of our Mergers & Acquisitions editorial experts. See our complete contributor list for more.
Request a Free Trial
MLex takes your privacy seriously and we will only use your personal information to provide you with relevant material. By submitting your details you are agreeing to our Terms and Conditions, our Privacy Policy and our Cookie Policy. We will not share your personal information with any 3rd parties.
However, as we believe that you may also have an interest in receiving information about similar products and services in the future we may from time to time contact you about related products. You can choose not to be contacted and manage your communications from MLex in our Preference Center
You can also phone us on:
UK (Toll Free) +44 800 999 3237
US (Toll Free) +1 800 356 6547
Hong Kong +852 2965 1424